Prothena Corporation plc reported significant financial changes in its latest quarterly filing, revealing total revenue of $51.1 million for the three months ended March 31, 2026, compared to $2.8 million for the same period in 2025. This increase was primarily driven by a $50 million milestone payment from Novo Nordisk related to the advancement of coramitug in the Phase 3 CLEOPATTRA clinical trial. Collaboration revenue, however, decreased to $1.0 million from $2.8 million year-over-year, reflecting the partial performance of the PRX019 Phase 1 Clinical Trial Obligation.
The company's operating expenses also saw a notable decline, totaling $21.0 million in Q1 2026, down from $68.4 million in Q1 2025. This reduction was largely attributed to decreased research and development costs, which fell by 75% to $12.6 million, as well as a decrease in general and administrative expenses. The restructuring plan initiated in June 2025, following the decision to discontinue the development of birtamimab, contributed to a net reduction in restructuring liabilities of approximately $4.2 million during the quarter.
Prothena's cash and cash equivalents increased to $329.5 million as of March 31, 2026, up from $307.5 million at the end of 2025. The company reported a net cash provided by operating activities of $28.9 million, primarily due to the milestone payment from Novo Nordisk. The total liabilities decreased to $37.3 million from $46.3 million, while total shareholders' equity rose to $312.6 million, reflecting the company's improved financial position.
Strategically, Prothena continues to advance its pipeline of therapeutic candidates targeting neurodegenerative diseases, including Parkinson's disease and amyloidosis. The company is actively engaged in collaborations with Roche and Bristol Myers Squibb, which are expected to provide additional funding through milestone payments and royalties. Prothena's management believes that its current cash position is sufficient to meet obligations for at least the next twelve months, although additional capital may be required for future research and development initiatives.
Looking ahead, Prothena remains focused on its clinical programs and potential product launches, with ongoing trials for prasinezumab and coramitug. The company is also exploring opportunities for further collaborations and partnerships to enhance its research capabilities and expand its market presence. However, management acknowledges the inherent risks and uncertainties associated with drug development, which may impact future financial performance and operational decisions.
About PROTHENA CORP PUBLIC LTD CO
Prothena Corporation plc is a biotechnology company specializing in protein dysregulation to develop therapies for neurodegenerative and rare amyloid diseases. Its pipeline includes antibody, vaccine, and small molecule programs targeting conditions like Alzheimer’s, Parkinson’s, and amyloidosis. The company leverages deep scientific expertise, strategic collaborations, and innovative targeting of pathogenic proteins to address unmet medical needs in serious, life-threatening diseases.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.